Leading the omega-3 pharma market
BASF supplies Maxomega™ EPA97 (Ethyl Icosapentate)
Over two decades ago, BASF introduced to the market Omacor®/Lovaza™, the first FDA and EU approved omega-3 based prescription drug. Our product is now represented in over 80 countries. We became world leaders in high-concentrate Omega-3 fatty acids for pharmaceuticals.
Leveraging world leading expertise, BASF is supplying Maxomega™ EPA97 (ethyl icosapentate), an ethylester oil.
Maxomega™ EPA97 (ethyl icosapentate) follows the specifications of the Japanese pharmacopoeia (JP).
BASF delivers premium products
- Long history of production and delivery of Omacor®/LovazaTM, the first FDA and EU approved omega-3 based prescription drug
- World leading expertise, experience & support for: Analysis, regulatory control, production and supply
- Long-term strategic commitment to the business